Jazz Pharmaceuticals

Youtube Subscribe

Open: 120.54 Close: 120.42 Change: -0.12

How to know if Jazz Pharmaceuticals Company Inc Stock is a risky investment without reading the whole internet.

This document will help you to evaluate Jazz Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Jazz Pharmaceuticals are: Jazz, Pharmaceuticals, analyst, JAZZ, predict, stock, company, …

Concept Map

Semantic Network

Stock Summary

SMG. shares rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. announced a deal with Jazz for its cancer drug, zanidatamab, which is currently being tested as being tested.

Today's Summary

Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance. The consensus among 8 analysts covering ( NASDAQ : JAZZ ) stock is to Buy JazZ.

Today's News

Bruce Cozadd co-founded Jazz Pharmaceuticals in 2003. Co-founded company dedicated to enabling patients to understand the holistic nature of their disease. Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance. Jazz is implementing a robust continuity plan in response to the COVID-19 pandemic. Jazz Pharmaceuticals ( NASDAQ:JAZZ – Get Free Report ) last announced its quarterly earnings data on Wednesday, November 8th. The company had a net margin of 2.11% and a return on equity of 22.23%. On average, research analysts predict that Jazz pharmaceuticals will post 15.41 earnings per quarter. Jazz Pharmaceuticals plc (JAZZ) presented updated positive data from a Phase 2a study for its breast cancer treatment candidate zanidatamab. At this time, Jazz Pharmaceuticals Cost of Revenue is fairly stable. A comprehensive analysis is essential to determine whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock. Key financial ratios are used to gauge profitability, efficiency, and growth potential. Wall Street analysts predict that Jazz Pharmaceuticals s share price could reach $192.38 by Dec 4, 2024. The consensus among 8 analysts covering ( NASDAQ : JAZZ ) stock is to Buy JazZ stock. On average, Wall Street. analysts predict. that Jazz. Pharmaceuticals. s revenue in 2023 is $3,794,392.

Stock Profile

" Jazz Pharmaceuticals plc (jazz) stock price, quote & news - stock analysis. jazz pharmaceuticals plcs plc. plc shares: SMG. Zymeworks shares rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. announced a deal with Jazz for its cancer drug, zanidatamab, which is currently being tested as being tested with Jazz. ZymWorks will receive $350 million from Jazz. Jazz Pharmaceuticals updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz updates 2021 guidance after closing acquisition ofGW Pharmaceuticals. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global pharmaceuticals company. The company is in the Health Care sector and Pharmaceuticals industry. Jazz Pharmaceuticals is looking for an experienced Senior Director, Global Workplace with broad responsibilities across all our sites to support continued growth. The Employees Retirement System of Texas has recently made headlines with its decision to reduce its holdings in Jazz Pharmaceutical. StockNews.com initiated coverage with a “strong-buy” rating for Jazz Pharmaceuticals. Cantor Fitzgerald maintained an “overweight” rating on the stock. The growing interest shown by institutional investors and hedge funds suggests positive sentiments. Jazz Pharmaceuticals ( NASDAQ:JAZZ – Get Free Report ) last released its quarterly earnings data on Wednesday, May 10th. CFO Renee D. Gala sold 6,000 shares of Jazz pharmaceuticals stock in a transaction on Thursday, May 18th."

Keywords

Are looking for the most relevant information about Jazz Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Jazz Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Jazz Pharmaceuticals are: Jazz, Pharmaceuticals, analyst, JAZZ, predict, stock, company, and the most common words in the summary are: jazz, pharmaceutical, stock, news, analyst, forecast, consultancy, . One of the sentences in the summary was: Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #jazz #pharmaceutical #stock #news #analyst #forecast #consultancy.

Read more →

Youtube Subscribe

---